Emerging evidence suggests that several anti-diabetic and weight-loss medications, particularly the GLP-1 receptor agonists semaglutide, dulaglutide, and liraglutide; the SGLT2 inhibitor empagliflozin; and the biguanide metformin, may be inversely associated with MS risk of progression [248]. This evidence concerns the gene GLP1R and myeloid sarcoma.